临床前CDMO研发筛选相关化合物

CDMO是Contract Development and Manufacturing Organization的缩写，即合同定制研发生产组织。它是一种为制药企业及生物技术公司提供医药（特别是创新药）工艺研发及制备、工艺优化、放大生产、注册和验证批生产以及商业化生产等定制服务的机构. 在传统代工基础上增加了研发和工艺优化能力，是高技术壁垒的工艺研发能力与规模生产能力的深度结合. 1, 工艺开发与优化：创新性合成路线设计、工艺参数优化. 2, 中试放大：实验室工艺向规模化生产的转化 3, 注册批生产：支持客户新药申报的验证批生产. 4, 商业化生产：药品上市后的大规模生产供应. 全球医药CDMO行业保持较高景气度。根据弗若斯特沙利文预测：2026年全球CDMO市场规模：预计达1,189亿美元 2033年全球CDMO市场规模：预计达3,385亿美元. CDMO作为医药产业链专业化分工的产物，已经从单纯的CMO代工模式升级为"研发+生产"一体化的高附加值服务。当前，在多肽、ADC、CGT等新型药物赛道的驱动下，全球及中国CDMO市场保持高速增长。中国CDMO企业凭借完整的供应链体系、工程师红利和一体化服务能力，全球市占率有望持续提升，行业正从"成本优势"竞争迈向"体系优势"竞争的新阶段。
如有产品调研服务, 请致函联系我们

客户展示

临床前CDMO研发化合物筛选

CAS: 6363-53-7

Maltose monohydrate

中文名称:麦芽糖
CAS号:6363-53-7
分子式: C12H24O12 分子量: 360.31
产品形式: Monohydrate
研发状态: Unknown status
研发用途: Diabetes Mellitus
研究机构: Lee''s Pharmaceutical Limited
研发日期: November 14 2017
研发阶段: Not Applicable
Maltose (Maltobiose, Malt Sugar, Beta-Maltose, D-Maltose) monohydrate, an non-essential nutrient that provides energy, is an intermediate in the intestinal digestion of glycogen and starch, and is found in germinating grains (and other plants and vegetables).

CAS: 63610-08-2

Indobufen

中文名称: 吲哚布芬
CAS号:63610-08-2
分子式: C18H17NO3 分子量: 295.33
产品形式: free base
研发状态: Unknown status
研发用途: Stable Coronary Heart Disease
研究机构: Henan Institute of Cardiovascular Epidemiology
研发日期: December 30 2021
研发阶段: Not Applicable
Indobufen (Ibustrin, K 3920) is a reversible platelet aggregation inhibitor. Indobufen is a reversible inhibitor of platelet cyclooxygenase (Cox) activity and suppresses thromboxane synthesis.

CAS: 635728-49-3

Darunavir Ethanolate

中文名称:地瑞那韦乙醇盐
CAS号:635728-49-3
分子式: C27H37N3O7S.C2H5OH 分子量: 593.73
产品形式: Ethanolate
研发状态: Not yet recruiting
研发用途: HIV Infections
研究机构: PENTA Foundation; AMS-PHPT Research Collaboration; Institut National de la Santé Et de la Recherche Médicale France; Centre Mère et Enfant de la Fondation Chantal Biya; Centre Hospitalier National d''Enfants Albert Royer; University of Zimbabwe Clinical Research Centre (UZCRC); Baylor College of Medicine
研发日期: Jun-24
研发阶段: Phase 1 : Phase 2
Darunavir Ethanolate (TMC-114, UIC 94017) is a nonpeptidic HIV protease inhibitor, used to treat HIV infection.

CAS: 635702-64-6

Pazopanib HCl (GW786034 HCl)

中文名称:盐酸帕唑帕尼
CAS号:635702-64-6
分子式: C21H23N7O2S.HCl 分子量: 473.98
产品形式: Hydrochloride
研发状态: Recruiting
研发用途: Hereditary Hemorrhagic Telangiectasia; Epistaxis; Anemia; Nosebleed; HHT
研究机构: Cure HHT
研发日期: May 8 2023
研发阶段: Phase 2 : Phase 3
Pazopanib HCl (GW786034 HCl) is a novel multi-target inhibitor of VEGFR1, VEGFR2, VEGFR3, PDGFR, FGFR, c-Kit and c-Fms with IC50 of 10 nM, 30 nM, 47 nM, 84 nM, 74 nM, 140 nM and 146 nM in cell-free assays, respectively. Pazopanib induces autophagic Type II cell death.

CAS: 635318-11-5

pomaglumetad (LY404039)

中文名称:(1R,4S,5S,6S)-4-氨基-2-硫杂双环[3.1.0]己烷-4,6-二甲酸 2,2-二氧化物
CAS号:635318-11-5
分子式: C7H9NO6S 分子量: 235.22
产品形式: Free Base
研发状态: Withdrawn
研发用途: Healthy Participants
研究机构: Denovo Biopharma LLC
研发日期: Aug-12
研发阶段: Phase 1
LY404039 is a potent agonist of recombinant human mGlu2/mGlu3 receptors with Ki of 149 nM/92 nM, shows >100-fold selectivity over ionotropic glutamate receptors, glutamate transporters, and other receptors. Phase 3.

CAS: 63-45-6

Primaquine Diphosphate

中文名称:磷酸伯安喹
CAS号:63-45-6
分子式: C15H21N3O.2H3O4P 分子量: 455.34
产品形式: Diphosphate
研发状态: Recruiting
研发用途: Vivax Malaria; G6PD Deficiency
研究机构: Menzies School of Health Research; Gadjah Mada University; Universitas Sumatera Utara; Indonesia University; Yayasan Pengembangan Kesehatan dan Masyarakat; Indonesian National Malaria Control Program Ministry of Health; National Research and Innovation Agency of Indonesia; Burnet Institute; University of Melbourne; Medicines for Malaria Venture; PATH; UNITAID; Institute of Tropical Medicine Belgium
研发日期: August 7 2023
研发阶段: Not Applicable
Primaquine Diphosphate is a transmission-blocking anti-malarial clinically available, displaying a marked activity against gametocytes of all species of human malaria.